Ther Adv Med Oncol: South Korea's large real-world data to evaluate the efficacy of Ramucirumab (Ramucirumab) combined with paclitaxel as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma (KCSG-ST19-16)

Ramucirumab as a single agent or in combination with paclitaxel is recommended as a second-line treatment for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
.

However, real data on Ramucirumab combined with paclitaxel in the treatment of large study cohorts are relatively limited

Ramucirumab as a single agent or in combination with paclitaxel is recommended as a second-line treatment for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

The study population included all gastric cancer or GEJ cancer patients who received ramucirumab + paclitaxel treatment in South Korea from May 1, 2018 to December 31, 2018
.

We included patients with advanced gastric or GEJ adenocarcinoma who had progressed after first-line platinum and fluoropyrimidine combined chemotherapy

The study population included all gastric cancer or GEJ cancer patients who received ramucirumab + paclitaxel treatment in South Korea from May 1, 2018 to December 31, 2018

The study included 1063 patients.

The best overall response of Ramucirumab combined with paclitaxel was CR in 9 cases (0.

Efficacy evaluation

Efficacy assessment Efficacy assessment

Based on a median follow-up of 7.
0 months (range 0 17.
2 months), the median progression-free survival (PFS) was 4.
03 months (95% CI 3.
80 4.
27), and the median OS was 10.
03 months (95% CI 9.
33 10.
73) )
.

Based on a median follow-up of 7.
0 months (range 0 17.
2 months), the median progression-free survival (PFS) was 4.
03 months (95% CI 3.
80 4.
27), and the median OS was 10.
03 months (95% CI 9.
33 10.
73) )
.

Based on a median follow-up of 7.

                 PFS and OS

                 PFS and OS PFS and OS

Neutrophils (44.
7%) are the most common in any grade of TRAE, and the incidence of febrile neutropenia is low (4.
5%)
.

Other common TRAEs of any grade include anemia (41.

Neutrophils (44.

Multivariate analysis found and determined 8 independent poor prognostic indicators for PFS and OS: ECOG≥2 (median PFS, 2.

        Multi-factor analysis of PFS and OS

Multi-factor analysis of PFS and OS

In summary, this large-scale real-world data further confirms the effectiveness of ramucirumab combined with paclitaxel in the second-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma
.

In summary, this large-scale real-world data further confirms the effectiveness of ramucirumab combined with paclitaxel in the second-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma
.

This large-scale real-world data further confirms the effectiveness of ramucirumab combined with paclitaxel in the second-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma

Original source:

Han HS, Kim BJ, Jee HJ, Ryu MH, Park SH, Rha SY, Kim JG, Bae WK, Lee KW, Oh DY, Kim IH, Sym SJ, Oh SY, Kim HS, Byun JH, Kim DS, Suh YJ , An H, Zang DY.
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).
Ther Adv Med Oncol.
2021 Sep 18 ;13:17588359211042812.
doi: 10.
1177/17588359211042812.
PMID: 34552667; PMCID: PMC8450614.

Han HS, Kim BJ, Jee HJ, Ryu MH, Park SH, Rha SY, Kim JG, Bae WK, Lee KW, Oh DY, Kim IH, Sym SJ, Oh SY, Kim HS, Byun JH, Kim DS, Suh YJ , An H, Zang DY.
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).
Ther Adv Med Oncol.
2021 Sep 18 ;13:17588359211042812.
doi: 10.
1177/17588359211042812.
PMID: 34552667; PMCID: PMC8450614.
Leave a message here